Basit öğe kaydını göster

The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

dc.contributor.authorPaydas, Semra
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorDEMİRKAN, FATİH
dc.contributor.authorSaydam, Giiray
dc.contributor.authorHAZNEDAROĞLU, İBRAHİM CELALETTİN
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorAKSU, SALİH
dc.contributor.authorŞAHİN, FAHRİ
dc.contributor.authorUz, Burak
dc.contributor.authorYavuz, Selim A.
dc.contributor.authorAtay, Hilmi
dc.contributor.authorKELKİTLİ, ENGİN
dc.contributor.authorPEHLİVAN, MUSTAFA
dc.contributor.authorAkay, Meltem O.
dc.contributor.authorGuray, Emel
dc.contributor.authorKahraman, Selda
dc.date.accessioned2021-03-06T12:27:16Z
dc.date.available2021-03-06T12:27:16Z
dc.date.issued2012
dc.identifier.citationAKSU S., ŞAHİN F., Uz B., Yavuz S. A. , Atay H., KELKİTLİ E., Turgut M., PEHLİVAN M., Akay M. O. , Guray E., et al., "The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia", UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, ss.8-14, 2012
dc.identifier.issn1306-133X
dc.identifier.othervv_1032021
dc.identifier.otherav_f3e9adf9-fdf9-4286-8ae0-f9c870739e06
dc.identifier.urihttp://hdl.handle.net/20.500.12627/159933
dc.identifier.urihttps://doi.org/10.4999/uhod.12004
dc.description.abstractWe report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleThe Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
dc.typeMakale
dc.relation.journalUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
dc.contributor.departmentTrakya Üniversitesi , ,
dc.identifier.volume22
dc.identifier.issue1
dc.identifier.startpage8
dc.identifier.endpage14
dc.contributor.firstauthorID203248


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster